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Abstract The visceral adiposity index, based on anthro-
pometric and metabolic parameters, has been shown to be
related to adipose tissue function and insulin sensitivity. We
aimed to evaluate the performance of the visceral adiposity
index in adult patients with growth hormone deﬁciency. We
enrolled 52 patients(mean age 51± 13 years) with newly
diagnosed growth hormone deﬁciency and 50 matched
healthy subjects as controls at baseline. At baseline and
after 12 and 24 months of treatment we evaluated anthro-
pometric measures, lipid proﬁle, glucose and insulin during
an oral glucose tolerance test, hemoglobin A1c, home-
ostasis model assessment estimate of insulin resistance,
quantitative insulin sensitivity check index, insulin sensi-
tivity index Matsuda, insulin-like growth factor-I and
visceral adiposity index. At baseline growth hormone
deﬁciency patients showed higher waist circumference (p<
0.001), low-density lipoprotein cholesterol (p< 0.001) and
visceral adiposity index (p= 0.003) with lower insulin
sensitivity index (p= 0.007) and high-density lipoprotein
cholesterol (p= 0.001) than controls. During growth hor-
mone treatment we observed a signiﬁcant increase in
insulin-like growth factor-I (p< 0.001), high-density lipo-
protein (p< 0.001) with a trend toward increase in insulin
sensitivity index (p= 0.055) and a signiﬁcant decrease in
total cholesterol (p< 0.001) and visceral adiposity index (p
< 0.001), while no signiﬁcant changes were observed in
other clinical and metabolic parameters. The visceral
adiposity index was the only parameter that signiﬁcantly
correlated with growth hormone peak at diagnosis (p<
0.001) and with insulin-like growth factor-I and insulin
sensitivity index both at diagnosis (p= 0.009 and p<
0.001) and after 12 (p= 0.026 and p= 0.001) and 24
months (p< 0.001 and p= 0.001) of treatment. The visceral
adiposity index, which has shown to be associated with both
insulin-like growth factor-I and insulin sensitivity, proved
to be the most reliable index of metabolic perturbation,
among the most common indexes of adiposity assessment
and a marker of beneﬁt during treatment in adult growth
hormone deﬁciency patients.
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Introduction
Growth hormone (GH) has a key metabolic role and adipose
tissue, like bone and muscle, is a major target for GH action
[1, 2]. Indeed, untreated GH deﬁciency (GHD) in adult life
is associated with abnormalities in body composition in
addition to other cardiovascular risk factors, such as altered
cardiac structure and function, dyslipidemia, glucose intol-
erance and insulin resistance and GH treatment (GHT)
exerts beneﬁcial effects on most of these alterations [3–6].
The visceral adiposity index (VAI) is a gender-speci-
ﬁcmathematical index based on simple anthropometric
[body mass index (BMI) and waist circumference (WC)]
and metabolic [triglycerides and high-density lipoprotein
(HDL) cholesterol] parameters. It has been proposed as a
reliable marker of adipose tissue function and distribution,
independently associated with cardiometabolic risk in the
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general population [7, 8]. The VAI has shown a strong
association with the insulin sensitivity degree, evaluated
with a euglycemic-hyperinsulinemic clamp, and with the
visceral adipose tissue measured with magnetic resonance
imaging (MRI) [9]. In addition, in healthy subjects fat
distribution and function, represented by the VAI, have
been found to be correlated with GH levels [10] and these
data conﬁrm the close interrelation between adiposity and
the GH axis [11]. The application of the VAI in particular
populations of patients with endocrine diseases character-
ized by a variable degree of cardiometabolic risk, such as
acromegaly, polycystic ovary syndrome, type 2 diabetes
and prolactinoma, has produced interesting results [12–16].
These have led to the hypothesis that the VAI could be
considered as a marker of adipose tissue dysfunction [17].
However, to date, there are no data about the VAI in GHD,
which is a clinical condition known to be associated with
both cardiometabolic risk and adipose dysfunction. Because
of the complexity of the evaluation of body fat with imaging
techniques, our hypothesis was that the VAI, as a measure
which expresses different metabolic parameters, could be
useful to provide reliable information on body fat dis-
tribution and cardiometabolic risk of GHD patients. Aiming
to evaluate the performance of the VAI in this setting, we
investigated the metabolic proﬁle and the VAI in a cohort of
adult patients with GHD before and during GHT.
Materials and methods
Subjects
In this prospective study, 52 non-diabetic patients with
newly diagnosed adult-onset severe GHD (29 females, 23
males; mean age 51± 13 years; range 26–72) consecutively
admitted to the Section of Endocrinology of the University
of Palermo between January 2010 and December 2013 and
treated with GH for at least 24 months were enrolled.
This group included 29 patients with a pituitary adenoma
who were treated with surgery over 12 months previously,
11 with compressive syndrome caused by a non-functioning
pituitary adenoma (NFPA), 6 with Sheehan syndrome,
4 with GHD due to traumatic brain injury and 2 with likely
idiopathic GHD.
Patients with associated other pituitary hormone deﬁ-
ciencies received adequate and stable hormone replacement
therapy with glucocorticoid (no.= 28; 54 %), thyroid (no.
= 8; 15 %)and gonadal (no. = 34; 65 %) hormones for more
than 6 months before starting GHT.
Particularly, among patients with concomitant centrala-
drenal insufﬁciency, they all received hydrocortisone
treatment with an average stable dose of 5 mg per m2of
body surface area per day.
Among patients with concomitant central hypogonadism,
20 males received testosterone enanthate at the ﬁxed
monthly dose of 250 mg, while 14 females received trans-
dermal estrogen and progesterone treatment, to avoid a
signiﬁcant impact on GH requirement.
Nine out of 11 patients with compressive syndrome (17%
of the entire group) received a stable weekly dose of
cabergoline (0.25 mg/ twice a week) due to concomitant
secondary hyperprolactinemia. Seven patients (13 %) had
an isolated GHD.
The baseline clinical characteristics of the 52 patients
with GHD are shown in Table 1.
Fifty healthy subjects, matched for age (mean age 49±
16 years; range 25–72), gender(28 females, 22 males)and
BMI, were consecutively recruited among the medical and
paramedical personnel of the department and their relatives
as a control group at baseline.
All subjects with a previous diagnosis of diabetes mel-
litus were excluded from this study to avoid the impact of
the diabetes treatment on metabolic parameters and because
Table 1 Baseline clinical characteristics of 52 patients with GHD
GHD patients
(no.= 52)
Gender
males 23 (44 %)
females 29 (56 %)
Mean ± SD
Age (years) 51± 13
BMI (Kg/m2) 27.3± 4.5
IGF-I (µg/l) 58.3± 23.4
IGF-IUNR 0.29± 0.16
GH peak after GHRH plus arginine test(µg/l) 2.3± 2.2
Patients with BMI< 25 Kg/m2 (no. 11) 4.05± 1.45
Patients with BMI≥ 25 and<30 Kg/m2 (no. 23) 2.10± 1.97
Patients with BMI≥ 30 Kg/m2 (no. 18) 1.95± 1.87
Etiological diagnosis of GHD no. (%)
Surgery 29 (56)
NFPA 11 (21)
Sheehan syndrome 6 (11)
TBI 4 (8)
Idiopathic 2 (4)
Pituitary deﬁciencies no. (%)
FSH/LH 34 (65)
ACTH 28 (54)
Hyperprolactinemia 9 (17)
TSH 8 (15)
Isolated GHD 7 (13)
UNR under normal range (ratio of the observed serum IGF-I levels to
the average of the normal range age-adjusted), NFPA non-functioning
pituitary adenoma, TBI traumatic brain injury
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of their inability to perform the oral glucose tolerance test
(OGTT), while all patients with evidence of newly diag-
nosed glucose abnormalities after OGTT (no. = 5; 9 %)were
treated with diet alone. Similarly, no patients with a pre-
vious diagnosis of dyslipidemia or receiving speciﬁc treat-
ment were included in the study. We ﬁrst diagnosed
dyslipidemia in 16 patients who had never received any
pharmacological treatment until the end of the study pro-
tocol to avoid the impact of the treatment on metabolic
parameters.
Among the patients affected by systemic hypertension
(no. = 21; 40 %), 13 received ﬁxed pharmacological treat-
ment with sartans and 8 with angiotensin-converting-
enzyme inhibitors and these doses did not change during the
entire follow-up.
At the time of hospitalization, a written informed consent
for the scientiﬁc use of the data was obtained from all
participants.
Study design
At baseline and after 12 and 24 months of GHT in all
patients we performed a complete clinical and metabolic
evaluation. At baseline the diagnosis of GHD was estab-
lished by the criteria of the Endocrine Society [18]. GHRH
plus arginine test was performed in all subjects. Arginine
(arginine hydrochloride, Salf, Bergamo, Italy) was given at
the dose of 0.5 g/Kg, up to a maximal dose of 30 g slowly
infused from time 0 to 30 min, while GHRH (Geref, Serono,
Rome, Italy and GHRH Ferring, Milan, Italy) was given at
the dose of 1 lg/Kg as i.v. bolus at time 0. Blood samples
were taken every 30 min from 0 up to 90 min. The highest
GH levels measured from time 30 to 90 min during the test
were taken for analysis as peak GH and the diagnosis of
GHD was made taking into account the BMI of patients
[19]. The mean GH peak was 4.05± 1.45 µg/l in the group
of 11 patients with BMI < 25 Kg/m2; 2.10± 1.97 µg/l in the
group of 23 patients with BMI≥ 25 and <30 Kg/m2; 1.95±
1.87 µg/l in the group of 18 patients with BMI ≥ 30 Kg/m2.
WC was measured at the midpoint between the lower rib
and the iliac crest. Systolic (SBP) and diastolic (DBP) blood
pressure was measured at the right arm, with the subjects in
a relaxed sitting position for 5 min. Three measurements
were taken and averaged to give blood pressure values used
in this analysis. The blood pressure values during the fol-
low-up, in patients under anti-hypertensive treatment, were
evaluated without drug changes.
After an overnight fast, lipid proﬁle [total cholesterol,
HDL, low-density lipoprotein (LDL) cholesterol and tri-
glycerides], glucose, insulin, Hemoglobin A1c (HbA1c) and
IGF-I were measured. We calculated the ratio of the
observed serum IGF-I levels to the average of the normal
range, age-adjusted, and the data were presented as IGF-I
under normal range (IGF-IUNR). We considered equal to 1
the perfectly average IGF-I value and <1 IGF-I levels below
the average.
Glucose tolerance was assessed by standard OGTT with
75 g of glucose diluted in 250 ml of saline solution, blood
glucose and insulin levels being measured every 30 min for
2 h. As surrogate estimates of insulin sensitivity we con-
sidered the homeostasis model assessment estimate of
insulin resistance (Homa-IR) [20], the quantitative insulin
sensitivity check index (QUICKI) [21] and the insulin
sensitivity index (ISI), a composite index derived from the
OGTT and validated by Matsuda and DeFronzo [22].
As the surrogate of visceral fat function, the VAI was
calculated as described [9] using the following formulas
differentiated according to gender, where triglyceridesand
HDL-cholesterol levels are expressed in mmol/l:
for males; VAI ¼ WC=39:68þ 1:88 ´ BMIð Þ½ 
´ triglycerides=1:03ð Þ ´ 1:31=HDLð Þ;
for females; VAI ¼ WC=36:58þ 1:89 ´BMIð Þ½ 
´ triglycerides=0:81ð Þ ´ 1:52=HDLð Þ:
The patients received GH once daily at bedtime with a
pen injection system. We used a tailored dose-titration
regimen with a starting dose of 0.20 and 0.30 mg/day in
males and females respectively and the dose was indivi-
dually titrated during the ﬁrst 3–6 months to achieve serum
IGF-I levels within the age-dependent laboratory reference
range. After dose titration, the mean daily GH dose was
0.40± 0.15 mg from months 6 to 12; 0.45± 0.10 mg/day
from months12 to 18; and 0.40± 0.10 mg/day from months
18 to 24. IGF-I levels remained within the normal range
during the entire study period.
The institutional Ethics Committee of the University of
Palermo approved this study.
Hormone and biochemical assays
All biochemical data were collected after overnight fasting.
Glucose, HbA1c and lipids were measured in the cen-
tralized accredited laboratories with standard methods.
Serum insulin was measured by enzyme-linked immuno-
sorbent assay (DRG Instruments GmbH, Germany). The
sensitivity of the method was 1 IU/ml. Serum GH levels
were measured by immunoradiometric assay using com-
mercially available kits (Radim, Italy). The sensitivity of the
assay was 0.04 µg/l. The intra and inter-assay coefﬁcients of
variation (CVs) were 2.5–3.9 and 3.8–5.0 %, respectively.
We reported GH concentrations in µg/l of IS 98/574. IGF-I
levels were measured by a chemiluminescent immuno-
metric assay (Immulite 2000; Diagnostic Products Corp.,
Los Angeles, CA) using murine monoclonal anti-IGF-I
Endocrine
antibodies. The standards were calibrated against the World
Health Organization second IS 87/518. The assay had an
analytical sensitivity of 20 μg/l. The intra and inter-assay
CVs were 2.3–3.9 % and 3.7–8.1 %, respectively.
Statistical analysis
The Statistical Packages for Social Sciences (SPSS) version
20 was used for data analysis. Baseline characteristics were
presented as mean± SD for continuous variables. Normal-
ity of distribution for the quantitative variables was assessed
with the Kolmogorov-Smirnov test. The differences
between groups (GHD patients at baseline and controls)
were evaluated with the t-Test, while the one-way analysis
of variance was used to evaluate the signiﬁcance of the
changes over time during GHT in the GHD group. The
Pearson’s correlation was performed among continuous
variables. A p value <0.05 was considered statistically
signiﬁcant.
Results
The clinical and biochemical features of control subjects
and GHD patients at diagnosis and during GHT are shown
in Table 2.
Clinical and hormonal parameters
At baseline GHD patients showed higher WC (95.5 ± 8.5
vs. 87.4± 12.3 cm; p< 0.001) than controls, without sig-
niﬁcant differences in BMI, SBP and DBP (Table 2). As
expected, GHD patients had signiﬁcantly lower IGF-I levels
(58.3 ± 23.4 vs. 192.4± 60.7 µg/l; p< 0.001), IGF-IUNR
(0.29 ± 0.16 vs. 0.96± 0.30; p< 0.001) and GH peak after
GHRH plus arginine (2.2± 2.2 vs. 40.7± 21.9 µg/l; p<
0.001) than controls.
BMI was signiﬁcantly correlated with GH peak after
GHRH plus arginine in both GHD patients (r−0.521; p=
0.002) and controls (r−0.746; p< 0.001), while it was only
Table 2 Clinical and biochemical features of control subjects and GHD patients at diagnosis and after 12 and 24 months of treatment
Controls
(no.= 50)
GHD patients
at baseline
(no.= 52)
GHD
patients at
12 months
(no.= 52)
GHD patients
at 24 months
(no.= 52)
p p*
Age (years) 49± 16 51± 13 – – 0.357 –
BMI (Kg/m2) 26.6± 5.4 27.3± 4.5 27.2± 4.7 27.6± 4.5 0.462 0.355
WC (cm) 87.4± 12.3 95.5± 8.5 95.2± 8.3 95.3± 8.4 <0.001 0.133
SBP (mmHg) 122± 8 118± 17 122± 13 121± 13 0.129 0.182
DBP (mmHg) 74± 9 70± 10 71± 9 69± 8 0.113 0.549
VAI 1.71 ± 0.63 2.22± 0.99 1.98± 0.67 1.94± 0.56 0.003 <0.001
IGF-I (µg/l) 192.4± 60.7 58.3± 23.4 148± 39 170± 26 <0.001 <0.001
IGF-IUNR 0.96 ± 0.30 0.29± 0.16 0.69± 0.14 0.79± 0.08 <0.001 <0.001
Glucose metabolism
Fasting glucose (mmol/L) 4.96 ± 0.50 4.82± 0.62 4.81± 0,49 4.99± 0,53 0.217 0.088
Fasting insulin (IU/ml) 8.7± 4.1 10± 3.5 10.3± 2.4 10.9± 2.5 0.082 0.050
HbA1c (%) 5.4± 0.4 5.4± 0.3 5.5 0.3 5.4± 0.3 0.400 0.160
Homa-IR 1.98 ± 1.06 2.17± 0.86 2.32± 0.74 2.27± 0.72 0.331 0.779
QUICKI 0.35 ± 0.03 0.34± 0.02 0.34± 0.02 0.34± 0.001 0.060 0.058
ISI-Matsuda 5.87 ± 1.57 4.94± 1.81 5.46± 1.18 5.47± 1.39 0.007 0.055
Lipid metabolism
Total cholesterol (mmol/L) 5.21 ± 0.75 5.54± 0.94 5.01± 0.57 4.81± 0.72 0.063 <0.001
HDL cholesterol (mmol/L) 1.39 ± 0.18 1.25± 0.28 1.31± 0.17 1.37± 0.18 0.001 <0.001
LDL cholesterol (mmol/L) 3.15 ± 0.75 4.27± 0.75 4.16± 0.58 3.95± 0.63 <0.001 0.076
Triglycerides (mmol/L) 3.33 ± 0.80 3.41± 0.98 3.31± 0.65 3.39± 0.50 0.665 0.119
BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, VAI visceral adiposity index
p= difference between controls and GHD patients at baseline
p*= difference over time during GHT in GHD patients
Data are presented as mean± standard deviation (SD)
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correlated with ISI in control subjects (r−0.321; p= 0.023)
(Table 3).
In the GHD group, IGF-I signiﬁcantly increased after 12
and 24 months of GHT (p< 0.001), while no signiﬁcant
changes were observed in WC, BMI, SBP and DBP during
GHT (Table 2).
Metabolic parameters
At baseline, we found no signiﬁcant differences in fasting
glucose, insulin, HbA1c, Homa-IR and QUICKI between
GHD patients and controls and no signiﬁcant change in
them occurred during GHT(Table 2). In GHD group we
found a signiﬁcantly lower ISI (4.94 ± 1.81 vs. 5.87± 1.57;
p= 0.007), which showed a trend toward increase during
GHT, although not statistically signiﬁcant (p= 0.055).
GHD patients at baseline showed signiﬁcantly lower
HDL (1.25± 0.28 vs. 1.39± 0.18 mmol/l; p= 0.001) and
higher LDL cholesterol (4.27 ± 0.75 vs. 3.15± 0.75 mmol/
l; p< 0.001) than controls, without signiﬁcant differences in
total cholesterol and triglycerides (Table 2).
HDL cholesterol was signiﬁcantly correlated, both in
GHD patients and controls, with GH peak after GHRH plus
arginine (r−0.349; p= 0.043 and r−0.385; p= 0.006,
respectively) and ISI (r−0.360; p= 0.009 and r−0.333; p=
0.018, respectively). Similarly, triglycerides were sig-
niﬁcantly correlated, in both GHD patients and controls,
with ISI (r−0.337; p= 0.015 and r−0.420; p= 0.003,
respectively), while LDL cholesterol was only correlated
with ISI in the control group (r−0.322; p= 0.023) (Table 3).
During GHT we found a signiﬁcant decrease in total cho-
lesterol and an increase in HDL cholesterol (both p< 0.001)
with a trend toward decrease in LDL cholesterol, although
not statistically signiﬁcant (p= 0.076) and without sig-
niﬁcant change in triglycerides (Table 2).
Both HDL cholesterol and triglycerides were sig-
niﬁcantly correlated with ISI (r−0.388; p= 0.005 and
r−0.368; p= 0.007) at 12 months of GHT (Table 4).
At baseline, the VAI was signiﬁcantly higher in GHD
patients compared to controls (2.22 ± 0.99 vs. 1.71± 0.63;
p= 0.003) and it signiﬁcantly decreased during GHT (p<
0.001).
In both GHD group and controls we found a signiﬁcant
negative correlation of the VAI with GH peak after GHRH
plus Arginine (r−0.620; p< 0.001 and r−0.414; p= 0.003,
respectively), IGF-I (r−0.375; p= 0.009 and r−0.461; p=
0.001) and ISI (r−0.589; p< 0.001 and r−0.579; p< 0.001)
(Table 3; Fig.1). Similarly, in the GHD group a signiﬁcant
negative correlation of the VAI with IGF-I (r−0.339; p=
0.026 and r−0.692; p< 0.001) and ISI (r−0.453; p= 0.001
Table 3 Correlation (univariate analysis) at baseline of the main
clinical and metabolic parameters with the hormonal levels (GH peak
and IGF-I) and ISI in controls and GHD patients
Independent variables Dependent variable GH peak
Control group GHD group
r p r p
WC (cm) −0.241 0.092 −0.265 0.130
BMI (Kg/m2) −0.746 <0.001 −0.521 0.002
VAI −0.414 0.003 −0.620 <0.001
HDL cholesterol (mmol/l) 0.385 0.006 0.349 0.043
LDL cholesterol (mmol/l) −0.103 0.475 0.285 0.108
Triglycerides (mmol/l) 0.124 0.397 0.116 0.514
IGF-I
WC (cm) −0.047 0.746 −0.123 0.403
BMI (Kg/m2) −0.132 0.362 −0.024 0.871
VAI −0.461 0.001 −0.375 0.009
HDL cholesterol (mmol/l) 0.092 0.523 0.133 0.367
LDL cholesterol (mmol/l) −0.265 0.063 0.057 0.706
Triglycerides (mmol/l) 0.007 0.961 −0.023 0.874
ISI
WC (cm) −0.177 0.220 −0.106 0.453
BMI (Kg/m2) −0.321 0.023 0.360 0.163
VAI −0.579 <0.001 −0.589 <0.001
HDL cholesterol (mmol/l) 0.333 0.018 0.360 0.009
LDL cholesterol (mmol/l) −0.322 0.018 0.112 0.435
Triglycerides (mmol/l) −0.420 0.003 −0.337 0.015
BMI body mass index, WC waist circumference, VAI visceral adiposity
index
Table 4 Correlation (univariate analysis) of the main clinical and
metabolic parameters with IGF-I levels and ISI in GHD patients during
GHT
Independent variables Dependent variable: IGF-I
12 months 24 months
r p r p
WC (cm) −0.147 0.345 −0.237 0.131
BMI (Kg/m2) −0.253 0.102 −0.260 0.137
VAI −0.339 0.026 −0.692 <0.001
HDL cholesterol (mmol/l) 0.109 0.485 0.072 0.652
LDL cholesterol (mmol/l) 0.072 0.646 −0.013 0.935
Triglycerides (mmol/l) −0.207 0.183 −0.062 0.696
ISI
WC (cm) −0.053 0.707 −0.131 0.355
BMI (Kg/m2) −0.122 0.413 −0.119 0.502
VAI −0.453 0.001 −0.558 0.001
HDL cholesterol (mmol/l) 0.338 0.005 −0.164 0.245
LDL cholesterol (mmol/l) 0.157 0.267 −0.026 0.857
Triglycerides (mmol/l) −0.368 0.007 −0.065 0.646
BMI body mass index, WC waist circumference, VAI visceral adiposity
index
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and r−0.558; p= 0.001) was maintained after 12 and 24
months of GHT, respectively (Table 4; Fig.2).
Discussion
We investigated metabolic proﬁle the visceral adipose
function, indirectly expressed by the VAI, in a group of
newly diagnosed adult patients with GHD. TheVAI was
found to be the parameter most closely related to insulin
sensitivity degree and hormonal levels. Indeed, in this study
the VAI proved to be inversely associated with GH peak,
IGF-I levels and insulin sensitivity at diagnosis and posi-
tively inﬂuenced by GHT.
The correlation between visceral adiposity and GH axis
highlights how GHD could be associated with a condition
of visceral adiposity dysfunction and metabolic risk. In this
connection, a clustering of cardiovascular clinical risk fac-
tors has been reported in GHD patients, mainly including
truncal adiposity and increased visceral fat, changes in body
composition and insulin resistance, negative changes in
lipid proﬁles and increased cardiovascular mortality
[23–25].
In addition, lifetime congenital untreated isolated GHD
in adults increases visceral adiposity and the activity of the
enzyme 11β-hydroxysteroid dehydrogenase, which converts
cortisone to cortisol, both linked to insulin resistance and
increased cardiovascular risk [26]. Subjects with congenital
untreated GHD due to a homozygous mutation in the
GHRH receptor gene present reduced beta-cell function and
higher frequency of impaired glucose tolerance [27], despite
these subjects also have normal bone status and do not
develop premature atherosclerosis [28].
To date, there is limited evidence and rarely coming from
randomized studies to consider GHT able to widely
improve cardiovascular risk factors and to decrease cardi-
ovascular morbidity and mortality. Consistent beneﬁcial
effects of GHT were variously reported on body composi-
tion, metabolism and cardiovascular risk factors [29–32],
although the prevalence of the metabolic syndrome in GHD
patients was found to be increased when compared to
healthy controls even after GHT, likely due to the dis-
cordant data about anthropometric parameters and glucose
metabolism [32–34]. Therefore, if the beneﬁcial effect of
GHT on lipid proﬁle is well established, other cardiovas-
cular risk factors may continue to deteriorate during GHT,
leading to a concern about the net beneﬁcial effects of GHT.
In addition, if the overt GHD in adults is frequently asso-
ciated with a well-known clinical syndrome, sometimes the
clinical picture of GHD or the metabolic effects of GHT
Fig. 1 Correlation (univariate analysis) at baseline between VAI and ISI Matsuda (ISI) a, b and between VAI and IGF-I levels c, d in control
subjects and GHD patients, respectively
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can-not amply manifested. Indeed, the overall cardiovas-
cular risk associated with GHD has been frequently asses-
sed by the prevalence of the overt metabolic syndrome, by
acclaimed lipid or glucose impairment or by increased BMI,
while the current study showed that a degree of risk in GHD
and the net beneﬁt of GHT can only be revealed by the
VAI.
We found a signiﬁcant higher WC, but not BMI, in GHD
patients compared to control subjects, without any sig-
niﬁcant change during GHT. However, WC did not corre-
late either with IGF-I or with insulin sensitivity. These data
are also in agreement with the main results on long-term
effects of GHT on BMI and WC, which appear to be
inconclusive. Indeed, both BMI and WC have been found to
be increased or unchanged during GHT [34, 35]. Conversely,
GHT has overt favorable effects on body composition,
mainly evaluated by dual-energy X-ray absorptiometry
(DEXA).
Several methods are available to evaluate body compo-
sition and in the literature DEXA is reported to be the best
currently available technique for detecting overt body
composition modiﬁcations [36]. However, DEXA cannot
distinguish between body cell mass and water and conse-
quently these data may not be accurate since GHT is
associated with an increase in the intracellular water
component [37]. Computed tomography and MRI are two
of the most sensitive methods that could lead to a reliable
estimate of visceral fat, but both procedures require
expensive specialized equipment and in this light the VAI is
a clinical index derived from MRI-based studies and
represents a better indicator of adipose dysfunction [17].
Indeed, despite a good correlation with abdominal adipos-
ity, such anthropometric measurements do not differentiate
visceral from subcutaneous adiposity [38]. Visceral obesity,
rather than peripheral/subcutaneous type, reﬂects the
metabolic changes in the body more accurately and for this
reason the visceral adipose tissue cannot be precisely pre-
dicted by BMI and WC in clinical practice. In our study, the
higher VAI in GHD patients at baseline and its signiﬁcant
reduction during GHT represents the most signiﬁcant
metabolic data and this ﬁnding supports the data of Di
Somma et al., who demonstrated a strong relationship
among GH axis, VAI and cardiometabolic risk in a cohort
of healthy subjects [10].
Our data conﬁrmed the mutual relationship between
GHD and adiposity, since a strong negative correlation was
found between VAI and GH peak at diagnosis, in agreement
with previous studies that demonstrated that GH peak after
GHRH plus arginine depends more on WC than on BMI
[39]. Ideally, the possibility to use one single value
Fig. 2 Correlation (univariate analysis) between visceral adiposity index (VAI) and ISI Matsuda (ISI) a, b and between VAI and IGF-I levels c, d
in GHD patients at 12 and 24 months of GHT, respectively
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representingat the same time BMI and WC could be very
useful, and in this light the VAI might represent a useful
tool. In this study, the VAI proved to be the parameter that
most strongly correlates with both insulin sensitivity and
hormonal parameters at baseline and also during the GHT,
while the other anthropometric (WC, BMI) and metabolic
parameters are not, or are only partially, related with them.
This ﬁnding is in agreement with the well-known strong
association between VAI and insulin sensitivity assessed by
ISI in the general population [9].
In agreement with other studies, we did not ﬁnd any
difference in SBP and DBP between GHD and controls or
signiﬁcant variations during GHT [40], while, as regards
lipid proﬁle, we found signiﬁcant results, as expected. GHD
patients usually have decreased HDL and increased LDL
cholesterol, as we found in our study, and the beneﬁcial
effects of GHT have been well documented, although a
limitation of most studies is the lack of data concerning
lipid-lowering treatment or the chronic use of these [35].
Our data, showing an improvement in total and HDL cho-
lesterol in patients not receiving speciﬁc treatment, are in
agreement with a series of studies which have conﬁrmed
that long-term GHT leads to a signiﬁcant improvement in
lipid proﬁle [41], although other studies did not report any
signiﬁcant effect [42, 43]. In addition, the neutral effect of
GHD and GHT on triglycerides observed in our study is in
agreement with the meta analysis performed by Maison et
al. [30].
The impairment in glucose metabolism, characterized by
insulin resistance and mainly due to increased BMI and
impaired body composition, has been often reported in
GHD [6, 44, 45], but discordant data have been shown as
regards the effect of GHT on it [35]. In our cohort of sub-
jects we found that the GHD group did not differ sig-
niﬁcantly from the control group for fasting glucose, insulin
and HbA1c levels and that these parameters did not sig-
niﬁcantly change during GHT. Similarly, we found no
difference in Homa-IR and QUICKI between the two
groups and no variation in them during GHT. Actually,
insulin resistance does not seem to be signiﬁcantly affected
during GHT if evaluated by the Homa index [43], while
onlythe use of the QUICKI showed a trend toward reduc-
tion in insulin sensitivity in a previous study [46]. In our
opinion, these controversial data may be due to the fact that
both the unfavorable counter-regulatory effect of GH on
glucose metabolism and the favorable variation of body
composition GH-induced must be taken into account. In
addition, notably, the estimates of insulin sensitivity derived
from fasting insulin and glucose have not always been
demonstrated to be useful surrogate measures of insulin
sensitivity. Furthermore, only few studies have used the
more reliable index ISI or the gold standard euglycemic
hyperinsulinemic clamp to evaluate insulin sensitivity
degree in this setting. Indeed, when we considered ISI, we
found lower insulin sensitivity in the GHD group compared
to controls, with a trend toward increase, although not sta-
tistically signiﬁcant, during GHT. These data are partially in
agreement with those of Arafat et al., who showed an
improvement in insulin sensitivity, evaluated by the clamp,
after low-dose GHT [47].
In conclusion, our study suggests that the VAI seems to
be the most reliable index of metabolic perturbation among
the most common indexes of adiposity assessment (i.e. WC,
BMI, lipids) and a marker of beneﬁt during treatment in
adult GHD patients. Indeed, the goals of GHT are to correct
the clinical and metabolic alterations described using IGF-I
levels as a marker of treatment. Therefore the use of the
VAI, which has shown to be correlated with both IGF-I and
insulin sensitivity, can be useful for the proper follow-up of
these patients in clinical practice. To date, if DEXA is
considered to be the best available technique for easily
measuring visceral fat mass, the VAI seems to be correlated
with both adiposity and hormonal-metabolic parameters.
However, given that these correlations are derived from
univariate analysis, whether the association between the
VAI and the hormonal and biochemical parameters is casual
or causal remains to be proven also through the availability
of instrumental data on body composition.
Limitations of this study are the open design, the lack of
follow-up in the control group and the lack of an untreated
GHD group due to ethical reasons because of the potential
beneﬁcial effects of GHT. Another limitation is probably
the lack of direct data on body composition, since MRI and
computed tomography, considered the gold standard for the
quantitative evaluation of adipose tissue, were not per-
formed; this is due to the fact that these two methods are
extremely expensive and too complicated for use in routine
practice. In addition, the body composition parameters
evaluated by densitometry were available only in a minority
of cases, for which they were not considered in the analysis
of results.
Future prospective large-scale studies aiming to identify
speciﬁc cut-off values of VAI and its potential predictive
role regarding cardiovascular risk in GHD patients must
necessarily take into account a longer follow-up.
Funding This research did not receive any speciﬁc grant from any
funding agency in the public, commercial or not-for-proﬁt sector.
Compliance with ethical standards
Conﬂict of interest All authors declare that there is no conﬂict of
interest that could be perceived as prejudicing the impartiality of the
research reported.
Author statement The authors hereby conﬁrm that neither the
manuscript nor any part of it has been published or is being considered
for publication elsewhere. By signing this letter each of us
Endocrine
acknowledges that he or she participated sufﬁciently in the work to
take public responsibility for its content.
Ethical approval All procedures performed were in accordance with
the ethical standards of the institutional and/or national research
committee and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all indivi-
dual participants included in the study.
References
1. A. Vijayakumar, R. Novosyadlyy, Y. Wu, S. Yakar, D. LeRoith,
Biological effects of growth hormone on carbohydrate and lipid
metabolism. Growth Horm IGF Res. 20(1), 1–7 (2010)
2. V.E. Chaves, F.M. Júnior, G.L. Bertolini, The metabolic effects of
growth hormone in adipose tissue. Endocrine 44(2), 293–302
(2013)
3. H. DeBoer, G.J. Blok, H.J. Voerman, P.M.J.M. DeVries, E.A.
Van der Veen, Body composition in adult growth hormone deﬁ-
cient men, assessed by anthropometry and bioimpedance analysis.
J. Clin. Endocrinol. Metab. 75, 833–837 (1992)
4. A. Colao, C. Di Somma, A. Cuocolo, M. Filippella, F. Rota,
W. Acampa, S. Savastano, M. Salvatore, G. Lombardi, The
severity of growth hormone deﬁciency correlates with the severity
of cardiac impairment in 100 adult patients with hypopituitarism:
an observational, case-control study. J. Clin. Endocrinol. Metab.
89, 5908–6004 (2004)
5. J.O. Johansson, J. Fowelin, K. Landin, I. Lager, B.A. Bengtsson,
Growth hormone deﬁcient adults are insulin resistant. Metabolism
44, 1126–1129 (1995)
6. F. Salomon, R.C. Cuneo, R. Hesp, P.H. Sonksen, The effects of
treatment with recombinant growth hormone on body composition
and metabolism in adults with growth hormone deﬁciency.
N. Engl. J. Med. 321, 1797–1803 (1989)
7. M.C. Amato, C. Giordano, M. Pitrone, A. Galluzzo, Cut-off
points of the visceral adiposity index (VAI) identifying a visceral
adipose dysfunction associated with cardiometabolic risk in a
Caucasian Sicilian population. Lipids Health Dis. 10, 183 (2011)
8. K.M. Knowles, L.L. Paiva, S.E. Sanchez, L. Revilla, T. Lopez, M.
B. Yasuda, N.D. Yanez, B. Gelaye, M.A. Williams, Waist cir-
cumference, body mass index, and other measures of adiposity in
predicting cardiovascular disease risk factors among Peruvian
adults. Intern. J. Hypertens. 24, 931402 (2011)
9. M.C. Amato, C. Giordano, M. Galia, A. Criscimanna, S. Vitabile,
M. Midiri, A. Galluzzo, AlkaMeSy Study Group: Visceral
Adiposity Index: a reliable indicator of visceral fat function
associated with cardiometabolic risk. Diabetes Care. 33(4),
920–922 (2010)
10. C. Di Somma, A. Ciresi, M.C. Amato, S. Savastano, M.C.
Savanelli, E. Scarano, A. Colao, C. Giordano, Alteration of the
growth hormone axis, visceral fat dysfunction, and early cardio-
metabolic risk in adults: the role of the visceral adiposity index.
Endocrine 49(2), 492–502 (2015)
11. S. Savastano, C. Di Somma, L. Barrea, A. Colao, The complex
relationship between obesity and the somatotropic axis: the long
end winding road. Growth Horm IGF Res. 24(6), 221–226 (2014)
12. A. Ciresi, M.C. Amato, G. Pizzolanti, C. Giordano Galluzzo,
Visceral adiposity index is associated with insulin sensitivity and
adipocytokine levels in newly diagnosed acromegalic patients. J.
Clin. Endocrinol. Metab. 97(8), 2907–2915 (2012)
13. A. Ciresi, M.C. Amato, R. Pivonello, E. Nazzari, L.F. Grasso,
F. Minuto, D. Ferone, A. Colao, C. Giordano, The metabolic
proﬁle in active acromegaly is gender-speciﬁc. J. Clin. Endocri-
nol. Metab. 98, E51–E59 (2013)
14. M.C. Amato, M. Verghi, A. Galluzzo, C. Giordano, The oligo-
menorrhoic phenotypes of polycystic ovary syndrome are char-
acterized by a high visceral adiposity index: a likely condition of
cardiometabolic risk. Hum. Reprod. 26(6), 1486–1494 (2011)
15. M. Bozorgmanesh, F. Hadaegh, F. Azizi, Predictive performance
of the visceral adiposity index for a visceral adiposity-related risk:
type 2 diabetes. Lipids Health Dis. 10, 88 (2011)
16. A. Ciresi, M.C. Amato, V. Guarnotta, F. Lo Castro, C. Giordano,
Higher doses of cabergoline further improve metabolic parameters
in patients with prolactinoma regardless of the degree of reduction
in prolactin levels. Clin. Endocrinol. (Oxf) 79(6), 845–852 (2013)
17. M.C. Amato, C. Giordano, Visceral adiposity index: an indicator
of adipose tissue dysfunction. Int J Endocrinol. 2014, 730827
(2014)
18. M.E. Molitch, D.R. Clemmons, S. Malozowski, G.R. Merriam, M.
L. Vance, Endocrine Society: Evaluation and treatment of adult
growth hormone deﬁciency: an Endocrine Society clinical practice
guideline. J Clin Endocrinol Metab. 96(6), 1587–1609 (2011)
19. G. Corneli, C. Di Somma, R. Baldelli, S. Rovere, V. Gasco, C.G.
Croce, S. Grottoli, M. Maccario, A. Colao, G. Lombardi,
E. Ghigo, F. Camanni, G. Aimaretti, The cut-off limits of the GH
response to GH releasing hormone-arginine test related to body
mass index. Eur. J. Endocrinol. 153, 257–264 (2005)
20. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F.
Treacher, R.C. Turner, Homeostasis model assessment: insulin
resistance and beta-cell function from fasting plasma glucose and
insulin concentrations in man. Diabetologia 28, 412–419 (1985)
21. A. Katz, S.S. Nambi, K. Mather, A.D. Baron, D.A. Follmann,
G. Sullivan, M.J. Quon, Quantitative insulin sensitivity check
index: a simple, accurate method for assessing insulin sensitivity
in humans. J Clin Endocrinol Metab. 85, 2402–2410 (2000)
22. M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained
from oral glucose tolerance testing: comparison with the eugly-
cemic insulin clamp. Diabetes Care 22, 1462–1470 (1999)
23. J.W. Tomlinson, N. Holden, R.K. Hills, K. Wheatley, R.N.
Clayton, A.S. Bates, M.C. Sheppard, P.M. Stewart, Association
between premature mortality and hypopituitarism. West Midlands
Prospective Hypopituitary Study Group. Lancet 357(9254),
425–431 (2001)
24. M. Gola, A. Giustina, Growth hormone deﬁciency and cardio-
vascular risk: do we need additional markers?. Endocrine 42,
240–242 (2012)
25. J. Isgaard, M. Arcopinto, K. Karason, A. Cittadini, GH and the
cardiovascular system: an update on a topic at heart. Endocrine
48(1), 25–35 (2015)
26. E. Gomes-Santos, R. Salvatori, T.O. Ferrão, C.R. Oliveira, R.D.
Diniz, J.A. Santana, F.A. Pereira, R.A. Barbosa, A.H. Souza, E.V.
Melo, C.C. Epitácio-Pereira, A.A. Oliveira-Santos, I.A. Oliveira,
J.A. Machado, F.J. Santana-Júnior, J.A. Barreto-Filho, M.H.
Aguiar-Oliveira, Increased visceral adiposity and cortisol to cor-
tisone ratio in adults with congenital lifetime isolated GH deﬁ-
ciency. J Clin Endocrinol Metab. 99(9), 3285–3289 (2014)
27. C.R. Oliveira, R. Salvatori, J.A. Barreto-Filho, I.E. Rocha, A.
Mari, R.M. Pereira, V.C. Campos, M. Menezes, E. Gomes, R.A.
Meneguz-Moreno, V.P. Araújo, N.T. Leite, A.C. Nascimento-
Junior, M.I. Farias, T.A. Viscente, R.D. Araújo, E.V. Melo, M.H.
Aguiar-Oliveira, Insulin sensitivity and β-cell function in adults
with lifetime, untreated isolated growth hormone deﬁciency.
J Clin Endocrinol Metab. 97(3), 1013–1019 (2012)
28. A.H. Souza, M.I. Farias, R. Salvatori, G.M. Silva, J.A. Santana, F.
A. Pereira, F.J. de Paula, E.H. Valença, E.V. Melo, R.A. Barbosa,
R.M. Pereira, M.B. Gois-Junior, M.H. Aguiar-Oliveira, Lifetime,
untreated isolated GH deﬁciency due to a GH-releasing hormone
receptor mutation has beneﬁcial consequences on bone status in
Endocrine
older individuals, and does not inﬂuence their abdominal aorta
calciﬁcation. Endocrine 47(1), 191–197 (2014)
29. A. Hazem, M.B. Elamin, I. Bancos, G. Malaga, G. Prutsky, J.P.
Domecq, T.A. Elraiyah, N.O. Abu Elnour, Y. Prevost, J.P.
Almandoz, C. Zeballos-Palacios, E.R. Velasquez, P.J. Erwin, N.
Natt, V.M. Montori, M.H. Murad, Body composition and quality
of life in adults treated with GH therapy: a systematic review and
meta-analysis. Eur J Endocrinol. 166(1), 13–20 (2012)
30. P. Maison, S. Grifﬁn, M. Nicoue-Beglah, N. Haddad, B. Balkau,
P. Chanson, Impact of growth hormone (GH) treatment on car-
diovascular risk factors in GH-deﬁcient adults: a Metaanalysis of
Blinded, Randomized, Placebo-Controlled Trials. J Clin Endo-
crinol Metab. 89(5), 2192–2199 (2004)
31. L. Giovannini, G. Tirabassi, G. Muscogiuri, C. Di Somma, A.
Colao, G. Balercia, Impact of adult growth hormone deﬁciency on
metabolic proﬁle and cardiovascular risk. Endocr J. 62(12),
1037–1048 (2015)
32. A.A. van der Klaauw, N.R. Biermasz, E.J. Feskens, M.B. Bos,
J.W. Smit, F. Roelfsema, E.P. Corssmit, H. Pijl, J.A. Romijn, A.
M. Pereira, The prevalence of the metabolic syndrome is increased
in patients with GH deﬁciency, irrespective of long-term sub-
stitution with recombinant human GH. Eur J Endocrinol. 156(4),
455–462 (2007)
33. A.F. Attanasio, D. Mo, E.M. Erfurth, M. Tan, K.Y. Ho, D.
Kleinberg, A.G. Zimmermann, P. Chanson, International Hypo-
pituitary Control Complications Study Advisory Board: Pre-
valence of metabolic syndrome in adult hypopituitary growth
hormone (GH)-deﬁcient patients before and after GH replacement.
J Clin Endocrinol Metab. 95(1), 74–81 (2010)
34. K.M. Claessen, N.M. Appelman-Dijkstra, D.M. Adoptie, F.
Roelfsema, J.W. Smit, N.R. Biermasz, A.M. Pereira, Metabolic
proﬁle in growth hormone-deﬁcient (GHD) adults after long-term
recombinant human growth hormone (rhGH) therapy. J Clin
Endocrinol Metab. 98(1), 352–361 (2013)
35. N.M. Appelman-Dijkstra, K.M. Claessen, F. Roelfsema, A.M.
Pereira, N.R. Biermasz, Long-term effects of recombinant human
GH replacement in adults with GH deﬁciency: a systematic
review. Eur J Endocrinol. 169(1), R1–14 (2013)
36. S.A. Henche, R.R. Torres, L.G. Pellico, An evaluation of patterns
of change in total and regional body fat mass in healthy Spanish
subjects using dual-energy X-ray absorptiometry (DXA). Eur J
Clin Nutr. 62, 1440–1448 (2008)
37. J. Moller, J.O. Jorgensen, N. Moller, K.W. Hansen, E.B.
Pedersen, J.S. Christiansen, Expansion of extracellular volume
and suppression of atrial natriuretic peptide after growth hormone
administration in normal man. J Clin Endocrinol Metab. 72(4),
768 (1991)
38. S.E. Taksali, S. Caprio, J. Dziura, S. Dufour, A.M. Calí, T.R.
Goodman, X. Papademetris, T.S. Burgert, B.M. Pierpont,
M. Savoye, M. Shaw, A.A. Seyal, R. Weiss, High visceral and
low abdominal subcutaneous fat stores in the obese adolescent: a
determinant of an adverse metabolic phenotype. Diabetes 57,
367–371 (2008)
39. A. Colao, C. Di Somma, S. Savastano, F. Rota, M.C. Savanelli, G.
Aimaretti, G. Lombardi, A reappraisal of diagnosing GH deﬁ-
ciency in adults: role of gender, age, waist circumference, and
body mass index. J. Clin. Endocrinol. Metab. 94(11), 4414–4422
(2009)
40. A. Chrisoulidou, S.A. Beshyah, O. Rutherford, T.J. Spinks, J.
Mayet, P. Kyd, V. Anyaoku, A. Haida, B. Ariff, M. Murphy, E.
Thomas, S. Robinson, R. Foale, D.G. Johnston, Effects of 7 years
of growth hormone replacement therapy in hypopituitary adults. J
Clin Endocrinol Metab. 85(10), 3762–3769 (2000)
41. M. Elbornsson, G. Götherström, I. Bosæus, B.Å. Bengtsson, G.
Johannsson, J. Svensson, Fifteen years of GH replacement
improves body composition and cardiovascular risk factors. Eur J
Endocrinol. 168(5), 745–753 (2013)
42. C. Spielhagen, C. Schwahn, K. Moller, N. Friedrich, T. Kohl-
mann, J. Moock, M. Kołtowska-Häggström, M. Nauck, M.
Buchfelder, H. Wallaschofski, The beneﬁt of long-term growth
hormone (GH) replacement therapy in hypopituitary adults with
GH deﬁciency: results of the German KIMS database. Growth
Horm IGF Res. 21(1), 1–10 (2011)
43. J. Roemmler, M. Kuenkler, H.J. Schneider, C. Dieterle, J. Scho-
pohl, Comparison of glucose and lipid metabolism and bone
mineralization in patients with growth hormone deﬁciency with
and without long-term growth hormone replacement. Metabolism
59(3), 350–358 (2010)
44. C. Di Somma, R. Pivonello, G. Pizza, A. De Rosa, G. Lombardi,
A. Colao, S. Savastano, Prevalence of the metabolic syndrome in
moderately-severely obese subjects with and without growth
hormone deﬁciency. J Endocrinol Invest. 33(3), 171–177 (2010)
45. R. Abs, A.F. Mattsson, M. Thunander, J. Verhelst, M.I. Góth, P.
Wilton, M. Kołtowska-Häggström, A. Luger, Prevalence of dia-
betes mellitus in 6050 hypopituitary patients with adult-onset GH
deﬁciency before GH replacement: a KIMS analysis. Eur J
Endocrinol. 168(3), 297–305 (2013)
46. C. Giavoli, S. Porretti, C.L. Ronchi, V. Cappiello, E. Ferrante, E.
Orsi, M. Arosio, P. Beck-Peccoz, Long-term monitoring of insulin
sensitivity in growth hormone-deﬁcient adults on substitutive
recombinant human growth hormone therapy. Metabolism 53(6),
740–743 (2004)
47. A.M. Arafat, M. Möhlig, M.O. Weickert, C. Schöﬂ, J. Spranger,
A.F. Pfeiffer, Improved insulin sensitivity, preserved beta cell
function and improved whole-body glucose metabolism after low-
dose growth hormone replacement therapy in adults with severe
growth hormone deﬁciency: a pilot study. Diabetologia 53(7),
1304–1313 (2010)
Endocrine
